Objective
The tremendous success with which antibiotics have been used to combat infectious diseases is under serious threat from the increasing development of antimicrobial resistance. Without new treatment approaches to address antimicrobial resistance, this threa t will continue to rise. To fight infectious diseases effectively in the future we have to broaden the approaches in therapeutic intervention. There are three ways along which the therapeutic intervention of infectious diseases can be broadened. The first is to design drugs that have a smaller chance for resistance-development (to target evolutionary conserved structures is one key element here). The second is to design drugs that are as different in mechanism of action as we can envision. The third is to c ombine drugs. AMIS (Antimicrobials by Immune Stimulation) combines these three strategies in a highly innovative approach. AMIS aims to use the strength of our own innate immune system to design antimicrobial drugs for future generations. Antimicrobial pr oteins in our immune system are often combined with inflammatory signals in one single molecule. AMIS will take that same approach and reshuffle different parts of different molecules to make novel effector molecules that still have these combined function s but are optimally adapted for therapeutic intervention. Within our innate immune system many molecules have been identified over the last years that are involved in direct or indirect clearance of bacteria. The consortium will select the most promising and innovative compounds with this dual mode of action and: - Design proteins with anti-microbial activity in combination with an inflammatory trigger, targeting extra cellular bacteria; - Design proteins with inflammatory priming capacity (without extra anti-microbial activity); targeting intracellular bacteria; - Discover new TLR and PGRP and FPR modulators to dampen inflammation.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2003-LIFESCIHEALTH-I
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
UTRECHT
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.